Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 264

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 10
Chunk 264
---
 United States is able to exercise primary supervision over its administration and one or more U. S. persons have the authority to control all of the substantial decisions of such trust, or if such trust has a valid election in effect under applicable U. S. Treasury Regulations to be treated as a U. S. person.

If a partnership (or any other entity or arrangement treated as a partnership for U. S. federal income tax purposes) holds the ordinary shares or ADSs, the tax consequences relating to an investment in the

ordinary shares or ADSs will depend in part upon the status of the partner and the activities of the partnership. Such a partner or partnership should consult its tax advisor regarding the specific tax considerations of acquiring, owning and disposing of the ordinary shares or ADSs in its particular circumstances.

Persons considering an investment in the ordinary shares or ADSs should consult their own tax advisors as to the particular tax consequences applicable to them relating to the acquisition, ownership and disposition of the ordinary shares or ADSs, including the applicability of U. S. federal, state and local tax laws, French tax laws and other non-U. S. tax laws.

This description does not address the U. S. federal estate, gift or alternative minimum tax considerations, the Medicare tax on net investment income or any U. S. state, local or non-U. S. tax considerations of the acquisition, ownership and disposition of the ordinary shares or ADSs.

This description is based on the U. S. Internal Revenue Code of 1986, as amended, or the Code, existing, proposed and temporary U. S. Treasury Regulations promulgated thereunder and administrative and judicial interpretations thereof, in each case as of the date hereof. All the foregoing is subject to change, which change could apply retroactively, and to differing interpretations, all of which could affect the tax considerations described below. There can be no assurances that the U. S. Internal Revenue Service, or the IRS, will not take a position concerning the tax consequences of the acquisition, ownership and disposition of the ordinary shares or ADSs or that such a position would not be sustained by a court. The Company has not obtained, nor does the Company intend to obtain, a ruling with respect to the U. S. federal income tax considerations of the purchase, ownership or disposition of its ordinary shares or ADSs. Accordingly, holders should consult their own tax advisors concerning the U. S. federal, state, local and non-U. S. tax consequences of acquiring, owning and disposing